James M Ford, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
- Since medical school
- 37 years
- Yale University School of Medicine, 1989
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ford’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G70477 · Current
Licensed to practise in California · since 1990 · expires 2028-11-30 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Medical Oncology
Original Medicare doctor bills
$17,314
Medicare paid this office $17,314 for 86 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (60+ min) | 70 | $14,207 | $203 |
| Long return visit (40+ min) | 17 | $3,108 | $173 |
Who their Medicare patients are
86 Original Medicare patients in 2024. Average age 71 · Women 45% · Also on Medicaid 17% · Health risk score 1.80. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: Cancer 65% · High blood pressure 58% · Coronary heart disease 28% · Depression 23% · Diabetes 22% · Chronic kidney disease 15%.
The office billed $89,176, Medicare allowed $22,229 and paid $17,314; for 88 services of 2 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 86 | 88 | 71 | 1.80 | $89,176 | $17,314 |
| 2023 | 199 | 200 | 73 | 1.55 | $193,030 | $32,221 |
| 2022 | 166 | 166 | 73 | 1.42 | $164,998 | $26,413 |
| 2021 | 182 | 184 | 72 | 1.54 | $179,466 | $28,610 |
| 2020 | 183 | 208 | 72 | 1.72 | $140,335 | $23,794 |
| 2019 | 89 | 104 | 70 | 1.63 | $15,037 | $10,555 |
| 2018 | 99 | 113 | 70 | 2.08 | $14,161 | $10,302 |
| 2017 | 84 | 94 | 70 | 1.83 | $21,330 | $8,551 |
| 2016 | 75 | 92 | 70 | 1.92 | $22,943 | $7,938 |
| 2015 | 60 | 102 | 70 | 1.58 | $22,406 | $7,116 |
| 2014 | 123 | 296 | 71 | 1.75 | $85,844 | $25,789 |
| 2013 | 64 | 184 | 71 | 1.80 | $47,233 | $14,405 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| New patient visit (60+ min) | 186 | $30,380 | $163 |
| Long return visit (40+ min) | 12 | $1,596 | $133 |
2022: 2 services
| New patient visit (60+ min) | 149 | $24,132 | $162 |
| Long return visit (40+ min) | 17 | $2,281 | $134 |
2021: 2 services
| New patient visit (60+ min) | 133 | $22,052 | $166 |
| Long return visit (40+ min) | 43 | $5,974 | $136 |
2020: 4 services
| New patient visit (60+ min) | 53 | $8,124 | $153 |
| Long return visit (40+ min) | 68 | $7,311 | $104 |
| New patient visit (45+ min) | 34 | $3,997 | $118 |
| Telehealth originating site facility fee | 14 | $298 | $21 |
2019: 3 services
| Long return visit (40+ min) | 46 | $4,745 | $101 |
| New patient visit (45+ min) | 21 | $2,449 | $117 |
| New patient visit (60+ min) | 15 | $2,285 | $152 |
2018: 3 services
| Long return visit (40+ min) | 45 | $4,344 | $94 |
| New patient visit (45+ min) | 37 | $4,029 | $109 |
| Return visit (30+ min) | 15 | $1,272 | $71 |
2017: 3 services
| Long return visit (40+ min) | 37 | $3,686 | $100 |
| New patient visit (45+ min) | 32 | $3,581 | $112 |
| Return visit (30+ min) | 15 | $945 | $63 |
2016: 3 services
| New patient visit (45+ min) | 39 | $4,499 | $115 |
| Long return visit (40+ min) | 14 | $1,387 | $99 |
| Return visit (30+ min) | 16 | $1,121 | $70 |
2015: 4 services
| Return visit (30+ min) | 20 | $1,705 | $66 |
| New patient visit (45+ min) | 14 | $1,620 | $116 |
| New patient visit (60+ min) | 13 | $1,483 | $114 |
| Short return visit (20+ min) | 15 | $1,365 | $44 |
2014: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $5,444 | $64 |
| New patient visit (60+ min) | 35 | $5,004 | $143 |
| Return visit (30+ min) | 24 | $3,846 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,643 | $173 |
| Long return visit (40+ min) | 28 | $2,763 | $89 |
| Hospital discharge day management, 30 minutes or less | 17 | $1,113 | $65 |
2013: 5 services
| Return visit (30+ min) | 22 | $4,140 | $66 |
| New patient visit (60+ min) | 18 | $2,381 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $2,297 | $62 |
| Long return visit (40+ min) | 14 | $1,339 | $96 |
| Short return visit (20+ min) | 15 | $938 | $43 |
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 11 Part D prescriptions in 2016. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2016 | 11 | None | 0% (0) | None | $7,654 |
| 2015 | 48 | None | None | 29% | $21,951 |
| 2014 | 104 | 28 | None | 19% | $38,818 |
| 2013 | 69 | 21 | None | None | $12,079 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2014: 2 drugs
| Creon | 13 | $7,171 | $552 |
| Lorazepam | 11 | $67 | $6 |
2013: 2 drugs
| Ondansetron | 11 | $326 | $30 |
| Prochlorperazine Maleate | 12 | $80 | $7 |
Money from drug and device companies
$94 in 2020
| 2020 | 1 | 1 | None | $94 |
| 2019 | 1 | 1 | None | $11 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Kerecis | Kerecis Omega3 Wound | $94 | 1 payment
|
See the published payment
| Kerecis | Meals · 2020-06-11 | Kerecis Omega3 Wound | $94 |
See earlier years (2019)
2019: $11
| Allergan | Vraylar | $11 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · A Phase 2 Study To Evaluate Safety and Antitumor Activity of Avelumab in Combination With Talazoparib in Patients With Brca Or Atm Mutant Tumors · 2020 | Their institution | $160,949 |
| PUMA BIOTECHNOLOGY, INC. · This Is An Open-Label, Non-Randomized, Multicenter, Multinational, Phase 2 Study · 2020 | Their institution | $125,950 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic Or Surgically Unresectable Solid Tumor Malignancies Harboring Activating Fgfr Mutations Or Translocations (Fight-207) · 2021 | Their institution | $121,298 |
| PFIZER INC. · A Phase 2 Study To Evaluate Safety and Antitumor Activity of Avelumab in Combination With Talazoparib in Patients With Brca Or Atm Mutant Tumors · 2019 | Their institution | $93,690 |
| Genentech, Inc. · My Pathway · 2020 | Their institution | $91,279 |
| Puma Biotechnology, Inc. · An Open-Label, Phase 2 Study of Neratinib in Patients With Solid Tumors · 2019 | Their institution | $90,834 |
| Genentech, Inc. · My Pathway A Study Evaluating Herceptinperjeta, Tarceva, Zelborafcotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors · 2019 | Their institution | $62,458 |
| PFIZER INC. · A Phase 2 Study To Evaluate Safety and Antitumor Activity of Avelumab in Combination With Talazoparib in Patients With Brca Or Atm Mutant Tumors Javelin Brcaatm · 2021 | Their institution | $56,767 |
| AstraZeneca UK Limited · Olaparib in Gbrca Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy · 2021 | Their institution | $53,574 |
| Genentech, Inc. · My Pathway · 2021 | Their institution | $34,951 |
| Genentech, Inc. · My Pathway · 2025 | Their institution | $33,961 |
| Genentech, Inc. · My Pathway · 2024 | Their institution | $29,144 |
| Genentech, Inc. · My Pathway · 2022 | Their institution | $24,134 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic Or Surgically Unresectable Solid Tumor Malignancies Harboring Activating Fgfr Mutations Or Translocations (Fight-207) · 2022 | Their institution | $20,789 |
| PUMA BIOTECHNOLOGY, INC. · An Open-Label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (Egfr, Her2, Her3) Mutations Or Egfr Gene Amplification · 2022 | Their institution | $20,419 |
| PUMA BIOTECHNOLOGY, INC. · An Open-Label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (Egfr, Her2, Her3) Mutations Or Egfr Gene Amplification · 2021 | Their institution | $13,741 |
| AstraZeneca UK Limited · Olaparib in Gbrca Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy · 2019 | Their institution | $13,232 |
| PFIZER INC. · A Phase 2 Study To Evaluate Safety and Antitumor Activity of Avelumab in Combination With Talazoparib in Patients With Brca Or Atm Mutant Tumors Javelin Brcaatm · 2022 | Their institution | $11,014 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic Or Surgically Unresectable Solid Tumor Malignancies Harboring Activating Fgfr Mutations Or Translocations (Fight-207) · 2023 | Their institution | $2,991 |
| Genentech, Inc. · My Pathway · 2023 | Their institution | $2,670 |
| AstraZeneca UK Limited · Olaparib in Gbrca Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy · 2022 | Their institution | $2,117 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1801922604
- Licence
- CA G70477California G70477: Current · expires 2028-11-30
- Trained
- Yale University School of Medicine, 1989 · 37 years ago
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G704770
- Taxonomy
- Medical oncology (207RX0202X); Federal specialty code 207SG0201X (207SG0201X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-26
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 7999 Gateway Blvd Ste 200, Newark, CA, 94560